What is Septerna?
Based in South San Francisco, CA, Septerna is a clinical-stage biotechnology firm dedicated to pioneering novel therapies for GPCR-related conditions. Leveraging its proprietary Native Complex Platform, Septerna is actively developing a portfolio of oral small-molecule drug candidates. These candidates target a range of therapeutic areas including endocrinology, immunology, inflammation, and metabolic diseases. The company pursues these developments both through internal initiatives and strategic partnerships, aiming to address unmet medical needs in complex disease areas.
How much funding has Septerna raised?
Septerna has raised a total of $538M across 3 funding rounds:
Series A
$100M
Series B
$150M
Stock Offering
$288M
Series A (2022): $100M with participation from Invus Financial Advisors, Samsara BioCapital, BVF Partners, and Third Rock Ventures
Series B (2023): $150M led by Samsara BioCapital, Third Rock Ventures, and RA Capital Management
Stock Issuance/Offering (2024): $288M supported by Cantor Fitzgerald, Cowen, and Wells Fargo Securities
Key Investors in Septerna
Cantor Fitzgerald
Cantor Fitzgerald is a financial services firm providing institutional debt, equity sales, trading, investment banking, and real estate private equity services.
Cowen
Cowen is an independent financial services firm offering investment banking, research, and investment management services.
Wells Fargo Securities
Wells Fargo Securities is a company operating in the Investment Banking industry, providing a range of financial services.
What's next for Septerna?
The substantial enterprise-level financing, particularly the recent strategic investment, positions Septerna for accelerated growth and pipeline advancement. This capital is expected to fuel the progression of its drug candidates through clinical trials and potentially expand its research and development capabilities. The company's focus on GPCR targets and its innovative platform suggest a strategic direction aimed at capturing significant market share in the biotechnology sector. Future developments will likely involve further clinical data readouts and potential collaborations, building on the momentum from its recent funding success.
See full Septerna company page
